February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
15 citations
,
April 2020 in “Intestinal Research” FMT for ulcerative colitis may also help with weight loss, hair loss, arthritis, and allergies.
71 citations
,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
6 citations
,
May 2018 in “Zeitschrift für Rheumatologie” A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.
February 2026 in “Frontiers in Immunology” Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
4 citations
,
January 2022 in “Dermatology Research and Practice” Methotrexate alone is as effective and safe as combining it with prednisolone for treating Lichen planopilaris.
68 citations
,
April 2012 in “Digestive and Liver Disease” Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
Hepatitis B vaccination can trigger HSP, and vitamin D correction and tonsillectomy can effectively manage it.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
26 citations
,
March 2003 in “Pediatrics” Oral steroids may effectively treat recurrent intussusception in children with ILH, possibly avoiding surgery.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.